Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2024, 2025.
Financials
Financial year 2025
Auximines Clinical Solutions from Zemst, company number BE0669694136, closed financial year 2025 with a result of € 55,415 after tax. For that financial year Auximines Clinical Solutions recorded a gross margin of € 88,478 and equity of € 182,677. Compared with financial year 2024, the result moved from € -74,522 to € 55,415. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 182,677
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 55,415
▲ still € 74,522 loss in 2024
Profit after tax over the fiscal year.
€ 38,187
▼ 18% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 48,529 paid out
88 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 118,115
▲ 11% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,242
▼ 91% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 12,181
▲ € 9,361 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 60,112 | € 36,673 | € -44,501 | € 88,478 | ▲ € 132,979 |
| Profit after taxes | € 218,018 | € 62,251 | € -74,522 | € 55,415 | ▲ € 129,937 |
| Equity | € 189,663 | € 250,314 | € 175,792 | € 182,677 | ▲ 4% |
| Total debts | € 21,158 | € 11,014 | € 53,860 | € 43,579 | ▼ 19% |
| Cash | € 84,108 | € 72,607 | € 46,308 | € 38,187 | ▼ 18% |
| Retained profit | € 171,063 | € 231,714 | € 157,192 | € 164,077 | ▲ 4% |
| Dividend | € 450,000 | € 1,600 | € 0 | € 48,529 | |
| Balance sheet total | € 210,821 | € 261,328 | € 229,652 | € 226,257 | ▼ 1% |
Key figures of Auximines Clinical Solutions, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Auximines Clinical Solutions?
What happened at Auximines Clinical Solutions in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Corrected annual accounts filed for financial year 2025. Source: NBB ↗
- Steven RAMAEL became a director. NBB
- New establishment in Zemst. KBO
- Vanja VAN ASCH became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 218,018 profit in 2022 to € 55,415 profit in 2025.
Paid € 94,979 in corporate taxes since 2022.
Best year ever: 2022, with € 218,018 profit.
Paid out € 500,129 in dividends to the owners in total.
A new publication or filing at Auximines Clinical Solutions? We notify you, reason included.
Follow Auximines Clinical SolutionsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Auximines Clinical Solutions are Vanja VAN ASCH and Steven RAMAEL.
Directors
According to the 2025 annual accounts
Vanja VAN ASCH
Director
since 2017
Steven RAMAEL
Director
since 2017
Establishments
Establishment units
Physical locations of this company
Voetbalstraat 17
1981 Zemst
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0669.694.136
- VAT number
- BE 0669.694.136
- Registered office
- Voetbalstraat 17, 1981 Zemst
- Names & denominations
- Auximines Clinical Solutions
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 January 2017
- Peppol
- Active · Active since 10 Dec 2025
- Contact
- [email protected]
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige dienstverlenende activiteiten op het gebied van informatie
Overige zakelijke dienstverlening, neg
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Adviesbureaus op het gebied van public relations en communicatie
+1